Attorney General Andy Beshear announced January 12 that his office has transferred nearly $335,000 to the state’s General Fund from a multistate settlement with Bristol-Myers Squibb for unfair or deceptive trade practices with its atypical antipsychotic drug, Abilify. The company allegedly engaged in unfair or deceptive trade practices when it marketed Abilify for use in elderly patients with symptoms consistent with dementia and Alzheimer’s disease with lack of FDA approval and without establishing the drug’s safety and effectiveness for those uses. Bristol-Myers Squibb will be prohibited from making false or misleading claims about the drug as well as limit financial incentives to sales representatives and health care providers and practices affecting off-label promotion.